top of page

Group

Public·26 members
Taras Evseev
Taras Evseev

Travoprost Buy


An overdose of travoprost ophthalmic is not expected to be dangerous. Seek emergency medical attention or call the Poison Help line at 1-800-222-1222 if anyone has accidentally swallowed the medication.




travoprost buy



It is not likely that other drugs you take orally or inject will have an effect on travoprost used in the eyes. But many drugs can interact with each other. Tell each of your healthcare providers about all medicines you use, including prescription and over-the-counter medicines, vitamins, and herbal products.


A fundamental determinant of pharmacological efficacy over time is compound stability, which may be affected by storage conditions, including ambient temperature.21 The package inserts for all three PGAs indicate that they should be stored at or below 25C after opening for up to 6 weeks in the case of latanoprost22 or for an unspecified period of time for bimatoprost23 and travoprost.24 However, unlike the other two drugs, latanoprost is stated to require refrigeration before opening,22 possibly owing to a lower thermal stability.


Studies aimed at assessing patient adherence with self-administration of topical ocular hypotensive medications suggest that over 40% of patients take their medications on 75% or less of the days that they are supposed to.35,36 It seems possible that compliance with drug administration might take precedence over drug storage and so one could expect that an even lower percentage of patients carefully store their drug bottles as directed. Our results suggest that this could seriously affect drug stability if the default storage conditions are at high temperature. In some regions throughout the United States, seasonal outdoor temperatures exceed 37C. Indoor temperatures can be even higher when air conditioning is not utilized, for instance, if no one is home during the day. Temperatures in enclosed spaces such as automobiles can easily rise to exceed 50C. In addition to storage temperature, exposure to UV radiation also has a significant effect on PGA stability. Indeed, Morgan et al.29 showed that exposure to UV radiation at levels similar to summer sunlight can degrade latanoprost at a rate corresponding to a T90 of just a few hours. Therefore, handling and storage of PGAs are likely to impact their efficacy. As both of these factors are time dependent, the impact of improper storage may be even further exacerbated by failure to discard unused medication after the recommended amount of time (6 weeks after opening for latanoprost,22 not indicated in the package inserts for bimatoprost23 or travoprost24). In light of this, proper storage of PGAs should be stressed by prescribing ophthalmologists.


Another consideration involving the stability of PGAs centers on the use of these compounds in geographic areas with limited resources. Glaucoma is a major cause of visual impairment throughout the world,1,2 including in developing countries where potent ocular hypotensive medications are not as readily available as in the US or Europe. The patent for latanoprost will be the first for the three PGAs to expire in 2011 (US Patent #5,296,504), making it available for generic production, whereas travoprost is protected by patent until at least 2013 (US Patent #5,510,383) and bimatoprost until at least 2014 (US Patent #5,688,819). In considering whether generic forms of topical prostaglandins might be useful and cost effective for the treatment of glaucoma in developing nations with extremely warm climates, the ability to transport and store these compounds (especially latanoprost and travoprost) at temperatures below 25C should be taken into account. If loss of efficacy resulting from reductions in drug concentration after extended periods of thermal stress proves to be problematic, it may be beneficial to package the drugs in smaller volumes that can be consumed more quickly after opening.


This medicine may cause the iris (colored part), eyelid, or eyelashes of your treated eye to turn brown. Your eyelashes may also become longer, thicker, and darker. Some of these changes may be permanent even if you stop using travoprost. Check with your doctor if you have any questions about this.


HOW TO USE: Apply this medication in the affected eye(s) usually once a day in the evening, or as directed by your doctor. Do not use travoprost more often because it will not work as well. To apply eye drops, wash your hands first. To avoid contamination, do not touch the dropper tip or let it touch your eye or any other surface. Remove contact lenses before using this medication if your brand contains the preservative benzalkonium chloride. This preservative can be absorbed by contact lenses. Wait at least 15 minutes after using this medication before putting your lenses back in. Tilt your head back, look upward and pull down the lower eyelid to make a pouch. Hold the dropper directly over your eye and place one drop into the pouch. Look downward and gently close your eyes for 1 to 2 minutes. Place one finger at the corner of your eye (near the nose) and apply gentle pressure. This will prevent the medication from draining out. Try not to blink and do not rub your eye. Repeat these steps for your other eye if so directed. Do not rinse the dropper. Replace the dropper cap after each use. If you are using another kind of eye medication (e.g., drops or ointments), wait at least 5 minutes before applying other medications. Use eye drops before eye ointments to allow the eye drops to enter the eye. Use this medication regularly in order to get the most benefit from it. Remember to use it at the same time each day. It is important to continue using travoprost even if you feel well. Most people with glaucoma or high pressure in the eye do not have symptoms.


SIDE EFFECTS: Blurred vision, eye redness/discomfort/itching, feeling as if something is in your eye, dry eyes, tearing, eyelid crusting, increase in eyelash number/length/thickness, darkening of the eyelashes and eyelids, eyelid changes, or increased sensitivity to light may occur. If any of these effects persist or worsen, notify your doctor or pharmacist promptly. This medication may slowly (over months to years) cause brown discoloration of the colored portion of the eye (iris). If you are using travoprost in only one eye, only that iris may change color. This color change may be permanent, but the long-term effects are uncertain. Notify your doctor if this occurs and schedule regular eye exams to monitor it. Remember that your doctor has prescribed this medication because he or she has judged that the benefit to you is greater than the risk of side effects. Many people using this medication do not have serious side effects. Tell your doctor immediately if any of these unlikely but serious side effects occur: vision changes, eye pain, swelling/redness of the eyelids. A very serious allergic reaction to this drug is unlikely, but seek immediate medical attention if it occurs. Symptoms of a serious allergic reaction may include: rash, itching/swelling (especially of the face/tongue/throat), severe dizziness, trouble breathing. This is not a complete list of possible side effects. If you notice other effects not listed above, contact your doctor or pharmacist. In the US - Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088. In Canada - Call your doctor for medical advice about side effects. You may report side effects to Health Canada at 1-866-234-2345.


PRECAUTIONS: Before using travoprost, tell your doctor or pharmacist if you are allergic to it; or to similar drugs (e.g., bimatoprost, latanoprost); or if you have any other allergies. This product may contain inactive ingredients (such as preservatives like benzalkonium chloride found in some brands), which can cause allergic reactions or other problems. Talk to your pharmacist for more details. Before using this medication, tell your doctor or pharmacist your medical history, especially of: eye problems (e.g., macular edema, iritis, uveitis, lens extraction/aphakia). If you develop an eye infection or injury, or have eye surgery, check with your doctor about the continued use of your current bottle of travoprost. You may be advised to start using a new bottle. This drug may cause temporary blurred vision. Do not drive, use machinery, or do any activity that requires alertness or clear vision until you are sure you can perform such activities safely. This medication should be used only when clearly needed during pregnancy. Discuss the risks and benefits with your doctor. It is not known if this drug passes into breast milk. Consult your doctor before breast-feeding.


Travoprost is a clear, colorless and viscous oil that is very soluble in acetonitrile, methanol, octanol, and chloroform. It is practically insoluble in water. Travoprost Ophthalmic Solution 0.004% is supplied as sterile, buffered aqueous solution of travoprost with a pH of approximately 6.0 and an osmolality of approximately 290 mOsmol/kg. Travoprost ophthalmic solution contains Active: travoprost 0.04 mg/mL; Preservative: benzalkonium chloride 0.015% w/v; Inactives: polyoxyl 40 hydrogenated castor oil, tromethamine, boric acid, mannitol, edetate disodium, sodium hydroxide and/or hydrochloric acid (to adjust pH)and water for injection.


Layout table for study information Study Type : Interventional (Clinical Trial) ActualEnrollment : 76 participants Allocation: Randomized Intervention Model: Crossover Assignment Masking: None (Open Label) Primary Purpose: Treatment Official Title: Randomized Crossover Trial Comparing the Hypotensive Effect of Generic Travoprost With That of the Brand Name Travoprost in Patients With Primary Open Angle Glaucoma or Ocular Hypertension Actual Study Start Date : July 1, 2016 Actual Primary Completion Date : September 12, 2017 Actual Study Completion Date : September 12, 2017 Resource links provided by the National Library of Medicine MedlinePlus Genetics related topics: Early-onset glaucoma Hypertension MedlinePlus related topics: Glaucoma Drug Information available for: Travoprost U.S. FDA Resources Arms and Interventions Go to Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information Arm Intervention/treatment Experimental: Brand name travoprostPatients will be randomized to either start in this arm for the first 3 weeks before the crossover to the other arm for the second 3 weeks or they will start in the other arm for the first 3 weeks before the crossover to this arm for the second 3 weeks. Drug: Brand name travoprostDepending on the arm, either brand name or generic Travoprost will be administered by the patient. After 3 weeks, the intraocular pressure will be measured and a crossover will happen. Patients having taken brand name Travoprost will be switched to generic Travoprost and vice versa. At 6 weeks, the intraocular pressure will be measured. Questionnaires on the comfort and intolerances of the drops will be administered at the visits of 3 and 6 weeks.Other Name: Travatan Z Experimental: Generic travoprostPatients will be randomized to either start in this arm for the first 3 weeks before the crossover to the other arm for the second 3 weeks or they will start in the other arm for the first 3 weeks before the crossover to this arm for the second 3 weeks. Drug: Generic travoprostDepending on the arm, either brand name or generic Travoprost will be administered by the patient. After 3 weeks, the intraocular pressure will be measured and a crossover will happen. Patients having taken brand name Travoprost will be switched to generic Travoprost and vice versa. At 6 weeks, the intraocular pressure will be measured. Questionnaires on the comfort and intolerances of the drops will be administered at the visits of 3 and 6 weeks.Other Name: Travoprost Outcome Measures Go to Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information Primary Outcome Measures : Intraocular Pressure [ Time Frame: After 3 weeks of either the brand name or generic travoprost ] Secondary Outcome Measures : Comfort and Intolerance to the Drops Questionnaire [ Time Frame: After 3 weeks of either the brand name or generic travoprost ]Patients will be asked about: 041b061a72


About

Welcome to the group! You can connect with other members, ge...
Group Page: Groups_SingleGroup
bottom of page